Eunae You

Eunae You

Auto-generated profile, based on publicly available information

Eunae You

Mass General Cancer Center Harvard Medical School 02129 Charlestown MA USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2024 in Cell
Verified
Journal Article
Closed access
EYEunae You
Eunae You
PDPatrick Danaher
Patrick Danaher
CLChenyue Lu
Chenyue Lu
SSSiyu Sun
Siyu Sun
LZLuli Zou
Luli Zou
DTDavid T. Ting
David T. Ting

11 February 2025 in Cancer Discovery
Verified
Journal Article
Open access
EYEunae You
Eunae You
BPBidish K. Patel
Bidish K. Patel
ARAlexandra S. Rojas
Alexandra S. Rojas
SSSiyu Sun
Siyu Sun
PDPatrick Danaher
Patrick Danaher
DTDavid T. Ting
David T. Ting
Repeat element viral mimicry is a common feature in pancreatic ductal adenocarcinoma (PDAC) that requires mechanisms to manage this repeat “viral” load and attenuate innate immune responses. In this study, we show that the long interspersed nuclear element 1 (LINE-1) open reading frame 1 protein (ORF1p) in PDAC cells plays a role in shielding repeat RNAs from activating a pathogen recognition receptor–mediated antiviral response that is independent of retrotransposition. Suppression of ORF1p using short hairpin RNA induces innate immune responses through the double-stranded RNA (dsRNA) sensors RIG-I and MAVS. Low ORF1p PDAC cell lines have suppressed expression of pathogen recognition receptors demonstrating convergent mechanisms to suppress innate immune signaling. Localization of ORF1p in processing bodies with the dsRNA helicase MOV10 was found to be important for these antiviral responses. Loss of ORF1p resulted in significant growth reduction in tumorspheres and mouse xenografts with an enriched epithelial cell state, and high ORF1p expression was associated with worsened survival in a cohort of human patients with PDAC. Significance: This study uncovers PDAC-specific mechanisms that dampen immune responses to viral-repeat RNA via long interspersed nuclear element 1 ORF1p. Suppression of ORF1p activates antiviral responses, reducing tumor growth and epithelial–mesenchymal transition. High ORF1p expression correlates with poor prognosis, highlighting its potential as a therapeutic target for PDAC.

2 May 2025
Verified
Other
Open access
EYEunae You
Eunae You
BPBidish K. Patel
Bidish K. Patel
ARAlexandra S. Rojas
Alexandra S. Rojas
SSSiyu Sun
Siyu Sun
PDPatrick Danaher
Patrick Danaher
DTDavid T. Ting
David T. Ting
Repeat element viral mimicry is a common feature in pancreatic ductal adenocarcinoma (PDAC) that requires mechanisms to manage this repeat “viral” load and attenuate innate immune responses. In this study, we show that the long interspersed nuclear element 1 (LINE-1) open reading frame 1 protein (ORF1p) in PDAC cells plays a role in shielding repeat RNAs from activating a pathogen recognition receptor–mediated antiviral response that is independent of retrotransposition. Suppression of ORF1p using short hairpin RNA induces innate immune responses through the double-stranded RNA (dsRNA) sensors RIG-I and MAVS. Low ORF1p PDAC cell lines have suppressed expression of pathogen recognition receptors demonstrating convergent mechanisms to suppress innate immune signaling. Localization of ORF1p in processing bodies with the dsRNA helicase MOV10 was found to be important for these antiviral responses. Loss of ORF1p resulted in significant growth reduction in tumorspheres and mouse xenografts with an enriched epithelial cell state, and high ORF1p expression was associated with worsened survival in a cohort of human patients with PDAC.Significance:This study uncovers PDAC-specific mechanisms that dampen immune responses to viral-repeat RNA via long interspersed nuclear element 1 ORF1p. Suppression of ORF1p activates antiviral responses, reducing tumor growth and epithelial–mesenchymal transition. High ORF1p expression correlates with poor prognosis, highlighting its potential as a therapeutic target for PDAC.

2 May 2025
Verified
Other
Open access
PDF file
EYEunae You
Eunae You
BPBidish K. Patel
Bidish K. Patel
ARAlexandra S. Rojas
Alexandra S. Rojas
SSSiyu Sun
Siyu Sun
PDPatrick Danaher
Patrick Danaher
DTDavid T. Ting
David T. Ting
Supplementary Table S3. Key resources table

17 June 2026
Verified
Other
Open access
EYEunae You
Eunae You
BPBidish K. Patel
Bidish K. Patel
ARAlexandra S. Rojas
Alexandra S. Rojas
SSSiyu Sun
Siyu Sun
PDPatrick Danaher
Patrick Danaher
DTDavid T. Ting
David T. Ting
Supplementary Table S1. List of proteins localized in PBs.

2 May 2025
Verified
Other
Open access
PDF file
EYEunae You
Eunae You
BPBidish K. Patel
Bidish K. Patel
ARAlexandra S. Rojas
Alexandra S. Rojas
SSSiyu Sun
Siyu Sun
PDPatrick Danaher
Patrick Danaher
DTDavid T. Ting
David T. Ting
Supplementary Figure S1. LINE-1 ORF1p function in PDAC and other cell lines. Supplementary Figure S2. Titration of Dox concentration to rescue ORF1p expression and evaluation of micronuclei-mediated STING activation. Supplementary Figure S3. ORF1p knockdown sensitizes repeat RNA-induced IFN response. Supplementary Figure S4. ORF1p cellular localization and evaluation of RNA editing protein function. Supplementary Figure S5. EM-related gene expression and response to drugs upon ORF1 knockdown. Supplementary Figure S6. ORF1 knockdown in vivo suppresses tumor progression by altering the TME. Supplementary Figure S7. Analysis of single-cell spatial neighborhoods.